Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen
Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Agopian, V. G., Harlander-Locke, M. P., Markovic, D., Zarrinpar, A., Kaldas, F. M., Cheng, E. Y., *et al*. (2017). Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. JAMA surgery, 152(1), 55–64. https://doi.org/10.1001/jamasurg.2016.3310

Aguilar, F., Hussain, S. P., & Cerutti, P. (1993). Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, *90*(18), 8586-8590. https://doi.org/10.1073/pnas.90.18.8586

Ahmad, S., & Seshadri, S. (2025). Hepatocellular Carcinoma in South Indian Population: Clinical Profile and AFP Correlation with Radiological Tumor Size. *J Pharm Bioallied Sci*, *17*(2), 1940–1945. https://doi.org/10.4103/jpbs.jpbs_1864_24

An, J., Chang, Y., Choi, G.H., Sohn, W., Song, J.E., Shin, H., *et al*., 2025. Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry. *J. Liver Cancer* 25: 109–122. doi:10.17998/JLC.2025.02.20

Attwa, M.H., & El-Etreby, S.A., 2015. Guide for diagnosis and treatment of hepatocellular carcinoma. *World J. Hepatol*: 1632-1651. doi:10.4254/wjh.v7.i12.1632

Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018). Hepatitis C virus and hepatocellular carcinoma: A narrative review. In *Journal of Clinical and Translational Hepatology,* 6 (1), 79-84 https://doi.org/10.14218/JCTH.2017.00067

Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., *et al*. (2015). A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. *Nature Genetics*, *47*(12), 1443–1448. https://doi.org/10.1038/ng.3417

Chen, T., Dai, X., Dai, J., Ding, C., Zhang, Z., Lin, Z., *et al*. (2020). AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. *Cell Death and Disease*, *11*(10), 822. https://doi.org/10.1038/s41419-020-03030-7

Chi, X., Jiang, L., Yuan, Y., Huang, X., Yang, X., Hochwald, S., *et al*., 2022. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. *BMC Gastroenterol.* 22:202. doi:10.1186/s12876-022-02279-w

UNIVERSITAS GADJAH MADA
Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Chu, Y. J., Yang, H. I., Wu, H. C., Liu, J., Wang, L. Y., Lu, S. N., *et al*. (2017). Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. *International Journal of Cancer*, *141*(4), 711-720. https://doi.org/10.1002/ijc.30782

Dahlan, M. (2016). Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. Jakarta: *Sagung Seto*, 58-61

Desai, A., Sandhu, S., Lai, J. P., & Sandhu, D. S. (2019). Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. In *World Journal of Hepatology*, 11(1), 1-18. https://doi.org/10.4254/wjh.v11.i1.1

Di Martino, M., Saba, L., Bosco, S., Rossi, M., Miles, K. A., Di Miscio, R., *et al*. (2014). Hepatocellular carcinoma (HCC) in non-cirrhotic liver: Clinical, radiological and pathological findings. *European Radiology*, *24*(7). 1446-1454 https://doi.org/10.1007/s00330-014-3173-2

Farazi, P. A., & DePinho, R. A. (2006). Hepatocellular carcinoma pathogenesis: From genes to environment. *Nat Rev Cancer*, *6*(9), 674–687. https://doi.org/10.1038/nrc1934

Favresse, J., Yolande, L., & Gras, J. (2021). Evaluation of a Capillary Electrophoresis System for the Separation of Proteins. *Journal of Applied Laboratory Medicine*, *6*(6), 674-687. https://doi.org/10.1093/jalm/jfab044

Force, M., Park, G., Chalikonda, D., Roth, C., Cohen, M., Halegoua-Demarzio, D., *et al*. (2022). Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. *Viruses*, *14*(4), 775. https://doi.org/10.3390/v14040775

Gajos-Michniewicz, A., & Czyz, M. (2024). WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. In *Genes and Diseases*, 11(2), 727-746. https://doi.org/10.1016/j.gendis.2023.02.050

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J. L., *et al*. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, *69*(1), 182-236. https://doi.org/10.1016/j.jhep.2018.03.019

Guan, M.C., Ding, Q., Zhao, Q., Li, N., Zhang, R.X., Zhang, S.Y., *et al*., 2025. Albumin-bilirubin grade as an alternative to Child–Pugh class for evaluating liver function within staging systems for hepatocellular carcinoma. *Discov. Oncol.* 16: 394. doi:10.1007/S12672-025-02187-X

Gurtatta, R.S., Whalen, S.E., & Ray, C.E., 2024. Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents. *Semin. Intervent. Radiol.* 41: 84. doi:10.1055/S-0043-1778660

UNIVERSITAS GADJAH MADA
Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hadziyannis, E., Sialevris, K., Georgiou, A., & Koskinas, J. (2013). Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels. *Oncology Reports*, *29*(2), 835-839. https://doi.org/10.3892/or.2012.2147

Hamid, A. S., Tesfamariam, S. G., Zhang, Y., & Zhang, Z. G. (2013). Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention (Review). *Oncology Letters*, *5*(4), 1087-1092. https://doi.org/10.3892/ol.2013.1169

Hassan, M. M., Kaseb, A., Etzel, C. J., El-Serag, H., Spitz, M. R., Chang, P., *et al*. (2013). Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. *Molecular Carcinogenesis*, *52*(1), 139-147. https://doi.org/10.1002/mc.22057

Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J. P., Chiang, D. Y., *et al*. (2009). Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Research*, *69*(18), 7385-7392. https://doi.org/10.1158/0008-5472.CAN-09-1089

Hsu, C.Y., Liu, P.H., Lee, Y.H., Hsia, C.Y., Huang, Y.H., Lin, H.C., *et al*., 2015. Using serum a-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: What is the most optimal cutoff? *PLoS One* 10 (3): e0118825. doi:10.1371/journal.pone.0118825

Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023). Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. In *Nature Reviews Gastroenterology and Hepatology*, 20(1), 37-49. https://doi.org/10.1038/s41575-022-00688-6

Kumar, R., Neibart, S.S., Kim, J., Mamidanna, S., Deek, M.P., & Jabbour, S.K., 2023. Predictive Value of Tumor Volume on Local Control in Hepatocellular Carcinoma Treated with Image Guided Hypofractionated Radiation Treatment. *Int. J. Radiat. Oncol.* 117. doi:10.1016/j.ijrobp.2023.06.2337

Li, C. L., Li, C. Y., Lin, Y. Y., Ho, M. C., Chen, D. S., Chen, P. J., *et al*. (2019). Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. *Hepatology*, *69*(2), 498-512. https://doi.org/10.1002/hep.30201

Lima, H.A., Endo, Y., Alaimo, L., Moazzam, Z., Munir, M.M., Shaikh, C., *et al*., 2022. Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma. *J. Gastrointest. Surg.* 26, 2512–2521. doi:10.1007/s11605-022-05469-9

Lin, C. W., Lin, C. C., Mo, L. R., Chang, C. Y., Perng, D. S., Hsu, C. C., *et al*. (2013). Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. *Journal of Hepatology*, *58*(4), 730-735. https://doi.org/10.1016/j.jhep.2012.11.045

UNIVERSITAS GADJAH MADA
Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Liu, P., Xie, S. H., Hu, S., Cheng, X., Gao, T., Zhang, C., *et al*. (2017). Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. *Oncotarget*, *8*(40), 68131-68137. https://doi.org/10.18632/oncotarget.19245

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., *et al*. (2008). Sorafenib in Advanced Hepatocellular Carcinoma. *New England Journal of Medicine*, *359*(4), 378–390. https://doi.org/10.1056/nejmoa0708857

Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky E., *et al*. (2021). Hepatocellular carcinoma. Nature Review Disease Primers, 7(6). https://doi.org/10.1038/s41572-020-00240-3

Mani, S. K. K., & Andrisani, O. (2018). Hepatitis b virus-associated hepatocellular carcinoma and hepatic cancer stem cells. In *Genes*, 9(3), 137. https://doi.org/10.3390/genes9030137

McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of Hepatocellular Carcinoma. *Hepatology*, *73*(1), 4–13. https://doi.org/10.1002/hep.31288

McHugh, P.P., Gilbert, J., Vera, S., Koch, A., Ranjan, D., & Gedaly, R., 2010. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. *HPB* 12: 56-61. doi:10.1111/j.1477-2574.2009.00128.x

Napitupulu, E.N. (2018). Korelasi serum alfa fetoprotein dengan ukuran dan jumlah tumor pada karsinoma hepatoseluler. Tesis. Universitas Gadjah Mada, Yogyakarta.

Nault, J. C., Mallet, M., Pilati, C., Calderaro, J., Bioulac-Sage, P., Laurent, C., *et al*. (2013). High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nature Communications*, (*4), 2218*. https://doi.org/10.1038/ncomms3218

Pak, V. N. (2018). The use of alpha-fetoprotein for the treatment of autoimmune diseases and cancer. In *Therapeutic Delivery*, 9(1), 37-46. https://doi.org/10.4155/tde-2017-0073

Park, S. J., Jang, J. Y., Jeong, S. W., Cho, Y. K., Lee, S. H., Kim, S. G., *et al*. (2017). Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. *Medicine (United States)*, *96*(11), 5811. https://doi.org/10.1097/MD.0000000000005811

Pessino, G., Scotti, C., & Maggi, M. (2024). Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets. In *Cancers*, 16(5), 901. https://doi.org/10.3390/cancers16050901

UNIVERSITAS GADJAH MADA
Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W., 2016. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open* 1: e000042. doi:10.1136/ESMOOPEN-2016-000042

Ratana-Amornpin, S., Vilaichone, R. K., Miftahussurur, M., Aumpan, N., Kaewkarnjanarat, K., Nun-anan, P., *et al*. (2021). Clinical features and overall survival of females with hepatocellular carcinoma: A retrospective study and review of the literature in the association of southeast asian nations. *International Journal of Women's Health*, vol 13, 717-725. https://doi.org/10.2147/IJWH.S311419

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., *et al*. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. In *Journal of Hepatology*, 76(3), 681-693. https://doi.org/10.1016/j.jhep.2021.11.018

Rusie, D., Stanciu, A.M., Toma, L., & Iliescu, E. L. (2022). Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals. *Cureus*, e24506. https://doi.org/10.7759/cureus.24506

Samant H, Amiri HS, & Zibari GB. (2021). Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. Journal of gastrointestinal oncology, 12(2), 361–373. https://doi.org/10.21037/jgo.2020.02.08

Sha, M., Wang, J., Cao, J., Zou, Z.H., Qu, X.Y., Xi, Z.F., *et al*., 2025. Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation. *Clin. Mol. Hepatol,* 31, 285-30*0.* doi:10.3350/CMH.2024.0323

Sharma, Y., Weaver, M.J., Ludwig, D.R., Fowler, K., Vachharajani, N., Chapman, W.C., *et al*., 2018. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. *Surg. (United States)* 163: 61-70. doi:10.1016/j.surg.2017.10.063

Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., *et al*. (2023). AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology*, *78*(6), 1922-1965. https://doi.org/10.1097/HEP.0000000000000466

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., *et al*. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 1922-1965. https://doi.org/10.3322/caac.21660

UNIVERSITAS GADJAH MADA
Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Sze, K. M. F., Ho, D. W. H., Chiu, Y. T., Tsui, Y. M., Chan, L. K., Lee, J. M. F., *et al*. (2021). Hepatitis B Virus–Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. *Hepatology*, *73*(1), 23-40. https://doi.org/10.1002/hep.31231

Talamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos-Molina, B., & Gurzov, E. N. (2023). Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma. In *JHEP Reports*, 5(9), e100811. https://doi.org/10.1016/j.jhepr.2023.100811

Tanaka, M., & Miyajima, A. (2016). Liver regeneration and fibrosis after inflammation. In *Inflammation and Regeneration*, 36(1), 19. https://doi.org/10.1186/s41232-016-0025-2

Toso, C., Meeberg, G., Hernandez-Alejandro, R., Dufour, J. F., Marotta, P., Majno, P., *et al*. (2015). Total Tumor Volume and Alpha-Fetoprotein for Selection of Transplant Candidates With Hepatocellular Carcinoma: A Prospective Validation. *Hepatology*, *62*(1), 158–165. https://doi.org/10.1002/hep.27787

Trinchet, J. C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., *et al*. (2015). Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). *Hepatology*, *62*(3), 737-750. https://doi.org/10.1002/hep.27743

Tu, J., Wang, B., Wang, X., Huo, K., Hu, W., Zhang, R., *et al*. (2024). Current status and new directions for hepatocellular carcinoma diagnosis. *Liver Research*, *8*(4), 218–236. https://doi.org/10.1016/j.livres.2024.12.001

Wong, R. J., Ahmed, A., & Gish, R. G. (2015). Elevated Alpha-Fetoprotein: Differential Diagnosis - Hepatocellular Carcinoma and Other Disorders. In *Clinics in Liver Disease*, 19(2), 309-323. https://doi.org/10.1016/j.cld.2015.01.005

Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: trends, risk, prevention and management. In *Nature Reviews Gastroenterology and Hepatology*, 16(10), 589-604. https://doi.org/10.1038/s41575-019-0186-y

Yen, Y.H., Kee, K.M., Li, W.F., Liu, Y.W., Wang, C.C., Hu, T.H., *et al*., 2023. Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. *Cancers (Basel).* 15; 1222. doi:10.3390/cancers15041222

Yeo, Y. H., Lee, Y. T., Tseng, H. R., Zhu, Y., You, S., Agopian, V. G., *et al*. (2024). Alpha-fetoprotein: Past, present, and future. *Hepatology communications*, *8*(5), e0422. https://doi.org/10.1097/HC9.0000000000000422

UNIVERSITAS
GADJAH MADA
**Korelasi Antara Rasio Volume Tumor Terhadap Volume Hati Berdasarkan Pemeriksaan CT Scan Abdomen
Multifase Dengan Nilai Alfa-Fetoprotein Pada Pasien Karsinoma Hepatoseluler**
Andre Darmawan, Prof. dr. Arif Faisal, Sp. Rad., Subsp. NKL (K), DHSM ; dr. Wigati Dhamiyati, Sp. Rad., Subsp.Onk
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Zakaria, H.M., Mohamed, A., Omar, H., & Gaballa, N.K., 2020. Alpha-fetoprotein level to total tumor volume as a predictor of hepatocellular carcinoma recurrence after resection. A retrospective cohort study. *Ann. Med. Surg.* 54: 109–113. doi:10.1016/j.amsu.2020.04.014

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., *et al*. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nature Medicine*, *23*(6), 703-713. https://doi.org/10.1038/nm.4333

Zhang, C. H., Cheng, Y., Zhang, S., Fan, J., & Gao, Q. (2022). Changing epidemiology of hepatocellular carcinoma in Asia. Liver international : official journal of the International Association for the Study of the Liver, 42(9), 2029–2041. https://doi.org/10.1111/liv.15251

Zhang, J. W., Feng, X. Y., Liu, H. Q., Yao, Z. W., Yang, Y. M., Liu, B., *et al*. (2010). CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE. *World Journal of Gastroenterology*, *16*(16), 2038-2045. https://doi.org/10.3748/wjg.v16.i16.2038